
High-cost medications necessary for treatment require close management to ensure patient safety and to adhere to payer-specific requirements.

High-cost medications necessary for treatment require close management to ensure patient safety and to adhere to payer-specific requirements.

Duchenne muscular dystrophy is an incurable neuromuscular disorder that can lead to cardiomyopathy, resulting in heart failure.

Pharmacists' accessibility and expertise in medication management make them ideal health care providers to discuss prevention strategies, medication adherence, and potential adverse effects.

The new designation for the selective PPAR⍺ antagonist follows positive phase 1b/2 clinical trial results.

It is important for pharmacists to understand what RSV is, who is most affected by it, and what options are out there to prevent serious disease.

Regulatory action could help patients with Hunter syndrome who have cognitive and behavioral complications and often do not have an effective treatment crossing the blood-brain barrier.

Palbociclib demonstrates safety and efficacy in combination with anti-HER2 and endocrine therapies.

Depression and cardiovascular disease are often linked, with research showing inflammation is common for the 2 disease states.

This association was also observed in siblings of children with autism spectrum disorder.

As an investigational monoclonal antibody, posdinemab targets the mid-domain of AD-specific phosphorylated tau.

The advisory emphasizes the need for a comprehensive approach to reducing alcohol-related cancer by combining prevention, education, and treatment to improve public health outcomes.

Data from a follow-up at 6 months show a reduced risk of all-cause mortality in heart attack patients with anemia who receive a liberal transfusion strategy compared with a restrictive one.

The data from the report show how nutritional choices compliment the use of glucagon-like peptide-1 receptor agonists and how health care providers can educate patients further.

Patients with acute coronary syndrome who were in the high quartile were at significantly higher risk for major adverse cardiovascular events (MACE).

The investigators note that the test can allow health care professionals to more accurately prescribe medication or treatments.

Intranasal epinephrine spray offers a needle-free option for anaphylaxis treatment.

Despite these concerns, experts have emphasized that the benefits of RSV vaccination outweigh potential risks for older adults, who are at heightened risk of severe RSV-related illness.

COVID-19 survivors deemed the most highly impacted and fearful also reported the lowest health-related quality of life scores, indicating an association.

AI is revolutionizing oncology drug development, enhancing therapeutic identification and reducing approval times, but use of this tool must be carefully implemented to mitigate risks and ensure regulatory compliance.

Approximately 61% of individuals said respiratory syncytial virus (RSV vaccination for adults 60 years and older is effective.

Sunvozertinib was originally approved in China, making it the world’s first and only oral treatment for these patients.

Management of acute otitis media in children involves evidence-based antibiotic prescribing.

The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.

These inequalities, which can include socioeconomic disparities, show neurological changes associated with aging and dementia.

Age, frequent snoring, hypertension, and poor glycemic control are associated with excessive daytime sleepiness.

A pooled analysis showed regular consumption of coffee and tea was associated with decreased risk of certain cancers.

The patient was hospitalized after exposure to an infected backyard flock.

If approved, the combination of avutometinib with defactinib could be the first FDA-approved treatment option for low-grade serous ovarian cancer.

Two cases of hospitalizations show mutations that may allow H5N1 to more easily target human cells.

Backed by positive results in multiple clinical trials, a new drug application (NDA) has been submitted for relacorilant for consideration by the FDA.